



TSE EURL

Istituto Zooprofilattico Sperimentale del
Piemonte, Liguria e Valle d'Aosta – Torino

Istituto Superiore di Sanità – Roma

Proficiency testing for veterinary laboratories

Histopathology and immunohistochemistry interpretation

Distribution date: December 2022

General comments

The TSE interpretation EQA is an exercise that allows all the NRLs to demonstrate their competence at reading stained/immunolabelled slides as part of their TSE diagnostic capability.

Attached below you will find a table summarising the results of the 2022 EQA round in conjunction with each participant ID.

The use of inconclusive/unsuitable for a case in which a definitive diagnosis is considered possible is not an 'incorrect' result in this context. A negative case called positive, or a positive case interpreted as negative are the only results which are considered 'incorrect'.

Correct and 'Safe' results are highlighted **green**. 'Incorrect' results are highlighted in **red**. Inconclusive or unsuitable returns are highlighted in **yellow**.

In the scrapie IHC category, readers were also invited to comment on whether the case is classical or atypical. Where a case is correctly diagnosed as positive, but subsequently misclassified or not classified, this has been identified on the table by highlighting the fonts of either "Pos-A" or "Pos-C" in **pink**.

You should each have received email notification of your unique 'ObserverID'. You will need this to identify your results in the table. Please keep this information safely – your ID will NOT change with subsequent rounds. If you have misplaced your ID then please contact Dr Giuseppe Ru (giuseppe.ru@izsto.it) directly, and the information will be re-sent. If you know of new staff who require to be added to the programme, or existing members of staff who no longer need to participate in this EQA then please contact us.

It is important to review any cases for which you have given an incorrect answer (highlighted in **red and **pink**) and fill the 'Slide review form' (at the end of this document) and return it to Giuseppe Ru (giuseppe.ru@izsto.it) and a copy to Barbara Iulini (barbara.iulini@izsto.it).**

Please use one form for each misclassified case.

This confirms for the EURL (and your own third party quality systems) that appropriate follow-on review of sections has taken place with those readers who require to re-read particular slides.



TSE EURL

Istituto Zooprofilattico Sperimentale del
Piemonte, Liguria e Valle d'Aosta – Torino


Istituto Superiore di Sanità – Roma

Comments on the results

The summary table below has grouped the cases according to species so if you wish to refer back to a particular case, please check the case number carefully at the top of the table.

Thank you.

Date: 23/01/2023

Barbara Iulini.....
Referent for Confirmatory Histopathology and Immunohistochemistry tests
Veterinary pathologist of Neuropathology Laboratory at IZSPLVA Italy

Giuseppe Ru.....
Director of TSE EURL

Case number	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15
Test Type	H&E	IHC	IHC	IHC	IHC	IHC	IHC	H&E	IHC	IHC	IHC	H&E	IHC	IHC	IHC
Gold standard result	Neg	Pos-C	Neg	Pos-C	Pos-C	Neg	Pos-A	Pos	Pos-C	Pos-C	Neg	Pos	Pos	Neg	Pos-A
Species	Bov	Ov	Bov	Ov	Ov	Ov	Ov	Bov	Ov	Ov	Ov	Ov	Bov	Ov	Ov
IHC result of all H&E sections															
User ID															
084	Neg	Pos-C	Neg	Pos-C	Pos-C	Neg	Pos-A	Pos	Pos-C	Pos-C	Inc	Pos	Pos	Neg	Inc
099	Neg	Pos-C	Neg	Pos-C	Pos-C	Neg	Pos-A	Pos	Pos-C	Pos-C	Neg	Pos	Pos	Neg	Pos-A
126	Neg	Pos-C	Neg	Pos-C	Pos-C	Neg	Pos-A	Pos	Pos-C	Pos-C	Neg	Pos	Pos	Neg	Pos-A
140	Neg	Pos-C	Neg	Pos-C	Pos-C	Neg	Pos-A	Pos	Pos-C	Pos-C	Neg	Pos	Pos	Neg	Pos-A
168	Neg	Pos-C	Neg	Pos-C	Pos-C	Neg	Pos-A	Pos	Pos-C	Pos-C	Neg	Pos	Pos	Neg	Pos-A
172	Neg	Neg	Neg	Pos-C	Pos-C	Neg	Pos-A	Neg	Pos-C	Pos-C	Neg	Pos	Pos	Neg	Pos-A
184	Neg	Pos-C	Neg	Pos-C	Pos-C	Neg	Pos-A	Pos	Pos-C	Pos-C	Neg	Pos	Pos	Neg	Pos-A
227	Neg	Pos-C	Neg	Inc	Pos-C	Neg	Pos-A	Pos	Pos-C	Pos-C	Neg	Inc	Pos	Neg	Pos-A
232	Neg	Pos-C	Neg	Pos-C	Pos-C	Neg	Pos-A	Pos	Pos-C	Pos-C	Neg	Pos	Pos	Neg	Pos-A
261	Neg	Pos-C	Neg	Pos-C	Pos-C	Neg	Pos-A	Pos	Pos-C	Pos-C	Neg	Pos	Pos	Neg	Pos-A
288	Neg	Pos-C	Neg	Pos-C	Pos-C	Neg	Pos-A	Pos	Pos-C	Pos-C	Neg	Pos	Pos	Neg	Pos-A
307	Neg	Pos-C	Neg	Inc	Pos-C	Neg	Pos-A	Pos	Pos-C	Pos-C	Neg	Pos	Pos	Neg	Pos-A
317	Neg	Pos-C	Neg	Pos-C	Pos-C	Neg	Pos-A	Uns	Pos-C	Pos-C	Neg	Pos	Pos	Neg	Pos-A
346	Uns	Pos-C	Inc	Pos-C	Pos-C	Neg	Pos-A	Pos	Pos-C	Pos-C	Inc	Pos	Pos	Neg	Pos-A
364	Neg	Pos-C	Neg	Pos-C	Pos-C	Neg	Pos-A	Pos	Pos-C	Pos-C	Neg	Pos	Pos	Neg	Pos-A
386	Neg	Pos-C	Neg	Inc	Pos-C	Neg	Pos-A	Pos	Pos-C	Pos-C	Inc	Pos	Pos	Neg	Pos-A
393	Neg	Pos-C	Neg	Pos-C	Pos-C	Neg	Pos-A	Pos	Pos-C	Pos-C	Neg	Pos	Pos	Neg	Pos-A
403	Neg	Pos-C	Neg	Pos-C	Pos-C	Uns	Pos-A	Pos	Pos-C	Pos-C	Neg	Pos	Pos	Neg	Pos-A
494	Inc	Pos-C	Neg	Pos-C	Pos-C	Neg	Pos-A	Inc	Pos-C	Pos-C	Neg	Pos	Inc	Uns	Pos-A
523	Inc	Pos-C	Neg	Pos-C	Pos-C	Neg	Pos-A	Uns	Pos-C	Pos-C	Neg	Pos	Pos	Neg	Pos-A
530	Neg	Pos-C	Neg	Pos-C	Pos-C	Neg	Pos-A	Pos	Pos-C	Pos-C	Neg	Pos	Pos	Neg	Pos-A
546	Neg	Pos-C	Neg	Pos-C	Pos-C	Neg	Pos-A	Inc	Pos-C	Pos-C	Neg	Pos	Pos	Uns	Pos-A
574	Inc	Pos-C	Neg	Pos-C	Pos-C	Neg	Pos-A	Inc	Pos-C	Pos-C	Neg	Pos	Pos	Uns	Pos-A
575	Uns	Pos-C	Inc	Pos-C	Pos-C	Neg	Pos-A	Pos	Pos-C	Pos-C	Inc	Pos	Pos	Neg	Pos-A
627	Neg	Pos-C	Neg	Pos-C	Pos-C	Neg	Pos-A	Pos	Pos-C	Pos-C	Neg	Pos	Pos	Neg	Pos-A
663	Neg	Pos-C	Neg	Pos-C	Pos-C	Neg	Pos-A	Inc	Pos-C	Pos-C	Neg	Pos	Inc	Uns	Pos-A
668	Neg	Pos-C	Neg	Pos-C	Pos-C	Neg	Pos-A	Pos	Pos-C	Pos-C	Neg	Pos	Pos	Neg	Pos-A
683	Inc	Pos-C	Neg	Pos-C	Pos-C	Neg	Pos-A	Inc	Pos-C	Pos-C	Inc	Inc	Pos	Neg	Pos-A
685	Neg	Pos-C	Neg	Pos-C	Pos-C	Neg	Pos-A	Inc	Pos-C	Pos-C	Neg	Pos	Pos	Neg	Pos-A
691	Uns	Pos-C	Pos	Pos-C	Pos-C	Neg	Pos-A	Inc	Pos-C	Pos-C	Inc	Pos	Pos	Inc	Pos-A
710	Neg	Pos-C	Neg	Pos-C	Pos-C	Neg	Pos-A	Pos	Pos-C	Pos-C	Inc	Pos	Pos	Neg	Pos-A
715	Neg	Pos-C	Neg	Pos-C	Pos-C	Neg	Inc	Pos	Pos-C	Pos-C	Neg	Pos	Pos	Neg	Pos-A
725	Neg	Pos-C	Neg	Pos-C	Pos-C	Neg	Pos-A	Pos	Pos-C	Pos-C	Neg	Pos	Pos	Neg	Pos-A
729	Neg	Pos-C	Neg	Pos-C	Pos-C	Neg	Pos-C	Pos	Pos-C	Pos-C	Inc	Pos	Pos	Neg	Pos-A
743	Neg	Pos-C	Neg	Pos-C	Pos-C	Neg	Pos-A	Neg	Pos-A	Pos-C	Neg	Pos	Pos	Neg	Pos-A
745	Neg	Neg	Neg	Pos-C	Pos-C	Neg	Pos-A	Neg	Pos-A	Pos-C	Neg	Pos	Pos	Neg	Pos-A
802	Neg	Pos-C	Neg	Pos-C	Pos-C	Neg	Pos-A	Neg	Pos-C	Pos-C	Neg	Pos	Pos	Neg	Pos-A
828	Neg	Pos-C	Neg	Pos-C	Pos-C	Neg	Pos-A	Pos	Pos-C	Pos-C	Neg	Pos	Pos	Neg	Pos-A
863	Neg	Pos-C	Neg	Pos-C	Pos-C	Neg	Pos-A	Neg	Pos-C	Pos-C	Neg	Pos	Pos	Neg	Pos-A
924	Neg	Pos-C	Inc	Pos-C	Pos-C	Neg	Inc	Inc	Pos-C	Pos-C	Neg	Pos	Pos	Neg	Inc
934	Neg	Pos-C	Neg	Pos-C	Pos-C	Neg	Pos-A	Pos	Pos-C	Pos-C	Neg	Pos	Pos	Neg	Pos-A
938	Neg	Pos-C	Neg	Pos-C	Pos-C	Neg	Pos-A	Pos	Pos-C	Pos-C	Neg	Pos	Pos	Neg	Pos-A
962	Neg	Pos-C	Neg	Pos-C	Pos-C	Neg	Pos-A	Pos	Pos-C	Pos-C	Neg	Pos	Pos	Neg	Pos-A



TSE EURL
Istituto Zooprofilattico Sperimentale del
Piemonte, Liguria e Valle d'Aosta – Torino

Istituto Superiore di Sanità – Roma

Histopathology and immunohistochemistry interpretation EQA 2022
Distribution December 2022

Slide review form

Observer ID:	
Date of EQA round:	
Case number:	
Original observer result:	
Intended (gold standard) result:	
Date of review:	
Further observer comments following review:	